Peptide Knowledge Base · Metabolic
VK2735 (Viking): what it is, what the evidence says, and its real status
An investigational dual GLP-1/GIP agonist (Viking) being developed in both injectable and oral forms.
Short version: a dual agonist whose category-disrupting wrinkle is an oral form. Investigational and not available, but worth watching, because 'GLP in a pill' changes the market.
Can you actually get it?
Plain-English verdict: Watch / education.
Regulatory status: Investigational (Phase 3) · Not yet approved.
Not available to prescribe. VK2735 is an investigational dual GLP-1/GIP agonist (Viking Therapeutics) in late-stage trials (VANQUISH), in injectable and oral forms. Not FDA-approved, not compoundable, education only.
How does VK2735 (Viking) work?
A dual GLP-1/GIP receptor agonist; the oral formulation is the strategically notable feature versus injectable-only incumbents.
What it does — and what it does not do
What it does: Studied for weight reduction; an oral version is in development.
What it does not do: It is not approved, not available, and the oral-vs-injectable comparison is not yet settled in trials.
How honest is the evidence?
Evidence grade B — Phase-2 data; Phase-3 ongoing, re-verify. Read our grading methodology for what each grade means.
What we still don't know: Oral bioavailability, durability, and long-term safety are still being established.
WADA status: Not prohibited.
How it is taken
What the literature reports: injectable weekly or oral daily (under study). Educational only, no dose figures.
Who should not take it
Investigational, safety not fully characterized; clinician-gated.
Sources
VK2735 Phase-2 program · VANQUISH (ongoing, re-verify against primary sources)
Compounded medications are not FDA-approved. We keep two signals separate and never collapse them: whether you can get something, and what the rule currently says. See the live FDA Peptide Tracker or the knowledge base.
Last reviewed 2026-08-11 · Peptós.LIFE · Not medical advice.